We developed GT-00AxIL15 as first-in-class IL-15-based immunocytokine targeting a tumor-associated, glycosylated epitope of MUC1 (TA-MUC1) to optimize tumor accumulation, efficacy, safety and half-life of IL-15 compared to untargeted therapeutics. Here, MUC1 is linked to neoplasm.